Why the study?
In failed CTO PCI, using a drug-coated balloon instead of a regular angioplasty balloon for subintimal plaque modification may facilitate a staged procedure by promoting better vessel healing.
Does drug-coated balloon plaque modification facilitate staged procedures in patients with failed coronary CTO PCI?
Does drug-coated balloon plaque modification facilitate staged procedures in patients with failed coronary CTO PCI?
Using a drug-coated balloon for subintimal plaque modification in failed CTO PCI is a novel concept that may promote better vessel healing and facilitate subsequent staged procedures.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for DCB plaque modification after failed CTO PCI; prospective trials needed before clinical adoption.
Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) is a technically challenging procedure. In failed cases, plaque modification strategy (also known as "investment procedure"), defined as the intentional dilation of the subintimal space through the CTO segment, can be applied. The typical dilation device used in this strategy is a regular angioplasty balloon (either semi- or noncompliant). Performing this technique with a drug-coated balloon (DCB) may facilitate a staged procedure by promoting a better vessel healing. Herein, we present three cases of failed CTO PCI, managed with DCB plaque modification, and their follow-up staged procedure.
No takes yet. Share an insight, caveat, or question.
Ybarra et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: